ReviewInternational journal of molecular sciences2024
Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Nd: YAG laser in the treatment of non-melanoma and melanoma skin cancers.Lasers in medical science · 2025Pooled it
- Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis.BMC cancer · 2024Pooled it
- Targeting Skin Cancer with Natural Bioactive Compounds: From Molecular Mechanisms to Application Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Serum metabolomic signatures of cutaneous malignancies identified by untargeted profiling.Medicine and pharmacy reports · 2026Article
- Intercellular mitochondrial transfer in melanoma progression and therapeutic resistance: mechanisms and targeting potential.Frontiers in oncology · 2026Review
- Diagnostic Challenges and Influencing Factors in Non-Melanoma Skin Cancers: A Retrospective Analysis of Basal Cell Carcinoma and Squamous Cell Carcinoma Cases.Cancer reports (Hoboken, N.J.) · 2025Article
- In Vivo Confocal Microscopy in the Surgical Treatment of Keratinocyte Carcinomas: A Systematic Review.Journal of clinical medicine · 2025Review
- Comparative study of early onset cancer burden between China and the United States from 1990 to 2021.Scientific reports · 2025Article
- Non-Melanoma Skin Cancer: Dermatoscopic Diagnostic Clues in Mexican Individuals Based on Fitzpatrick Skin Phototypes.Journal of clinical medicine · 2025Article
- Basal Cell Carcinoma Arising in a Previous Full-Thickness Graft Donor Site: A Case Report and Comprehensive Literature Review.Journal of clinical medicine · 2025Review
- Review
- Article
- Exosomes: innovative biomarkers leading the charge in non-invasive cancer diagnostics.Theranostics · 2025Review
- Surgical Textbook Outcomes in the Era of Neoadjuvant Systemic Treatment for Skin Cancers.Journal of clinical medicine · 2024Review
- Review
- Reconstructive Techniques Following Malignant Eyelid Tumour Excision-Our Experience.Journal of clinical medicine · 2024Article
- Deep neural network-based robust framework for automated skin lesion segmentation and analysis.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer encompasses a range of cutaneous malignancies, with non-melanoma skin cancers (NMSCs) being the most common neoplasm worldwide. Skin exposure is the leading risk factor for initiating NMSC. Ultraviolet (UV) light induces various genomic aberrations in both tumor-promoting and tumor-suppressing genes in epidermal cells. In conjunction with interactions with a changed stromal microenvironment and local immune suppression, these aberrations contribute to the occurrence and expansion of cancerous lesions. Surgical excision is still the most common treatment for these lesions; however, locally advanced or metastatic disease significantly increases the chances of morbidity or death. In recent years, numerous pharmacological targets were found through extensive research on the pathogenic mechanisms of NMSCs, leading to the development of novel treatments including Hedgehog pathway inhibitors for advanced and metastatic basal cell carcinoma (BCC) and PD-1/PD-L1 inhibitors for locally advanced cutaneous squamous cell carcinoma (cSCC) and Merkel cell carcinoma (MCC). Despite the efficacy of these new drugs, drug resistance and tolerability issues often arise with long-term treatment. Ongoing studies aim to identify alternative strategies with reduced adverse effects and increased tolerability. This review summarizes the current and emerging therapies used to treat NMSC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.